Degron Therapeutics is discovering and developing a new class of targeted protein degradation therapeutics small molecule molecular glue degrader (MGD) drugs. Degron has assembled a team of world-class scientific leaders and industry veterans, bringing its in-depth knowledge in the MGD space to the identification and validation of new MGD targets, particularly those disease drivers but undruggable or insufficiently drugged by other modalities, and to the discovery of novel selective MGD compounds to address unmet medical needs in all therapeutic areas.
In the past, MGDs have been discovered serendipitously. The rational design of MGDs has been extremely challenging due to the complexity of ternary structure formed by E3 ligase-MGD-target Until now.
Differentiated GlueXplorer™ MGD discovery platform enabled by:
- Proprietary and structurally differentiated glue library with 10,000 compounds
- Multiple complementary screening and validation platforms
- Large data sets for AI/Machine Learning
To date, Degron has developed a robust and differentiated pipeline of First-in-Class MGDs for important disease targets.
2021
2021
Founded in 2021
Robust MGD discovery platform
$34.5M
$34.5M
Capital raised: $34.5 million
10,000+
10,000+
Compounds in structurally differentiated MGD
library: >10,000 compounds
9
9
Neo-glue targets validated: 9
deep scientific knowledge
Founded based on 20+ years of Cereblon ubiquitin ligase research from Professor Yong Cang's lab.
PROPRIETARY AND STRUCTURALLY DIFFERNTIATED GLUE LIBRARY
Degron's library started from a novel chemical core that is differentiated from that of the IMiDs. Degron has expanded the diversity (about 60+ diverse cores) and number of compounds (10,000+) in the library, which continues to grow.
MULTIPLE COMPLEMENTARY SCREENING PLATFORMS
Degron uses multiple different but complementary strategies. In addition to target-based compound screen approach that most MGD companies use, Degron also applies phenotypic and proteomic screens to identifying more novel targets.
LARGE DATA SETS FOR AI/ML INSIGHTS
With the large number of assays and proprietary compounds, Degron has generated tremendous amount of data for developing AI/Machine Learning insights.
ROBUST PIPELINE OF FIRST-IN-CLASS TARGETS
Degron's technology platform allows for discovering and validating many new disease targets, most of which are undruggable targets not discovered by other MGD companies.
NEWS
NEWS
July 15, 2024
Degron Therapeutics Participated at UBS Virtual Targeted Protein Degradation Day
Degron Therapeutics Inc. CEO & Co-founder, Lily Zou, PhD, participated in a fireside chat at the Virtual Targeted Protein Degradation (TPD) Day hosted by th...
May 23, 2024
Degron Therapeutics Announces Multi-Target Collaboration and Exclusive License Agreement w...
Collaboration will leverage Degron's GlueXplorer® platform to discover novel molecular glue degraders for multiple targets in oncology, neuroscience, and inflam...
December 18, 2023
Degron Therapeutics won the 2023 BRACE Award Venture Competition along with the investment...
Degron Therapeutics was selected as the winner of the 2023 BRACE Award Venture Competition after thr
Contact us
